HEAD AND NECK SQUAMOUS CELL CARCINOMA

This study is for people with HPV-positive head and neck cancer who have had surgery and normally need radiation or chemoradiation afterward. Researchers want to see if giving a lower radiation dose can reduce long-term side effects without increasing the chance of the cancer com…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Technische Universität Dresden • Aim: Disease control

Last updated May 16, 2026 22:33 UTC

New drug combo shows promise for Hard-to-Treat cancers

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control

Last updated May 16, 2026 22:33 UTC

New hope for head and neck cancer: drug combo trial launches

This study tests a new combination of two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix can shrink tumors or slow the disease. About 60 adu…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated May 16, 2026 22:32 UTC

New drug targets Hard-to-Treat cancers with genetic weakness

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated May 16, 2026 22:32 UTC

New pill aims to shrink Hard-to-Treat cancers

This study tests an experimental pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and see if it is safe and can shrink tumors. About 220 people with specific genetic mutations will take the drug by mouth. Thi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control

Last updated May 16, 2026 22:32 UTC

New DNA vaccine combo aims to fight hard-to-treat head and neck cancer

This study tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in adults with advanced head and neck cancer caused by HPV types 16 or 18. Participants must have already tried platinum chemotherapy. The goal is to see if…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control

Last updated May 16, 2026 22:32 UTC

Engineered immune cells take on Hard-to-Treat cancers in early trial

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control

Last updated May 16, 2026 22:31 UTC

New drug BL-B01D1 targets Hard-to-Treat cancers in early trial

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control

Last updated May 16, 2026 22:31 UTC

New drug CTX-8371 tested in patients with advanced cancers

This study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck, or skin can…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control

Last updated May 16, 2026 22:31 UTC

New drug aims to supercharge immune cells against Hard-to-Treat cancers

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated May 16, 2026 22:30 UTC

New drug targets Hard-to-Treat cancers with rare mutation

This early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control

Last updated May 16, 2026 22:29 UTC

Can less radiation beat head and neck cancer? new study aims to find out

This study tests a new approach for people with certain head and neck cancers: using lower doses of radiation and chemotherapy, followed by surgery to remove any remaining cancer in the neck. The goal is to see if this gentler treatment can still control the cancer while reducing…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated May 16, 2026 22:29 UTC

Triple therapy aims to shrink advanced head and neck tumors

This study tests a combination of three treatments—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 adults with advanced head and neck cancer that has returned or spread. The goal is to see if this mix can s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control

Last updated May 16, 2026 22:29 UTC

New drug shows promise for Tough-to-Treat head and neck cancer

This study tests a new drug called petosemtamab against standard treatments for people with advanced head and neck cancer that has returned or spread and is no longer curable. About 500 adults who have already tried immunotherapy and chemotherapy will be randomly assigned to rece…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated May 16, 2026 22:28 UTC

Could a chemo drug boost radiation for head and neck cancer survivors?

This study compares radiation therapy alone versus radiation plus the chemotherapy drug cisplatin in people with stage III-IVA head and neck cancer who have already had surgery to remove their tumor. About 189 participants will be randomly assigned to one of the two treatments. T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control

Last updated May 16, 2026 22:28 UTC

New pill shows promise in battling Hard-to-Treat cancers

This study tests a new oral drug, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors or slow cancer growth. About 200 adults with specific cancers like ovarian, lung, or breas…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control

Last updated May 16, 2026 22:27 UTC

Virus therapy takes on advanced cancers in first human trial

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated May 16, 2026 22:27 UTC

New cocktail of cancer drugs shows promise in head and neck tumors

This study tests whether combining three different medicines can shrink tumors in people with head and neck cancer that has spread or come back. About 90 adults will receive either a two-drug or three-drug combination, or a single drug alone. The goal is to see if the combination…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated May 16, 2026 22:26 UTC

New antibody drug enters human trials for Hard-to-Treat cancers

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control

Last updated May 16, 2026 22:26 UTC

New drug combo shows promise for tough head and neck cancers

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 with advanced hea…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated May 15, 2026 11:57 UTC

New combo therapy aims to harness immune system against HPV-driven throat cancer

This study tests a new drug, CUE-101, alone or with pembrolizumab, in 30 people with newly diagnosed, advanced HPV-16 head and neck cancer that cannot be surgically removed. The goal is to see if these treatments can boost the body's immune cells to fight the tumor before standar…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control

Last updated May 15, 2026 11:57 UTC

New drug combo before surgery shows promise against head and neck cancer

This study tests whether giving two drugs (cetuximab and cemiplimab) before surgery can help shrink tumors in people with head and neck squamous cell carcinoma. About 21 adults will receive the drugs before their planned surgery. The goal is to see if this approach is safe and le…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated May 15, 2026 11:56 UTC

New tumor injection shows promise for advanced cancers

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: OncoNano Medicine, Inc. • Aim: Disease control

Last updated May 15, 2026 11:56 UTC

New virus therapy targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The mai…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control

Last updated May 15, 2026 11:55 UTC

New drug BL-M24D1 enters early human testing for hard-to-treat cancers

This early-phase trial tests a new drug called BL-M24D1 in about 16 people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of whether the drug shrinks tumors. Participants must…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated May 15, 2026 11:54 UTC

Radioactive seeds plus immunotherapy take on hard-to-treat head and neck cancer

This study tests a new approach for people with head and neck cancer that has come back or spread and cannot be removed by surgery. Tiny devices that give off a special type of radiation are placed directly into the tumor, and patients also receive an immunotherapy drug called pe…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control

Last updated May 15, 2026 11:54 UTC

Could less radiation be safer? new trial aims to shrink treatment zones without raising cancer return risk

This study tests whether giving radiation only to high-risk areas after surgery for head and neck cancer can lower side effects without increasing the chance of cancer coming back. About 50 adults with certain types of head and neck cancer will receive a personalized radiation pl…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Olgun Elicin • Aim: Disease control

Last updated May 15, 2026 11:54 UTC

New antibody combo targets Hard-to-Treat cancers

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Zumutor Biologics Inc. • Aim: Disease control

Last updated May 15, 2026 11:53 UTC

Could Low-Dose radiation boost cancer treatment before surgery?

This study is for people with operable head and neck squamous cell carcinoma. It compares two treatment approaches given before surgery: one combines low-dose radiotherapy with targeted therapy and immunotherapy, the other uses only targeted therapy and immunotherapy. The goal is…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated May 15, 2026 11:53 UTC

New drug targets Hard-to-Treat cancers in early trial

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated May 14, 2026 12:06 UTC

New drug duo aims to fight advanced head and neck cancer

This study tests two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors and improve survival. About 70 adults who have not had prior systemic treatment will take p…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated May 14, 2026 12:05 UTC

New combo therapy aims to shrink head and neck tumors

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has returned or spread. Participants must have already tried immunotherapy and platinum chemotherapy. The goal is to see if the combination shrinks tumors and is s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated May 14, 2026 12:05 UTC

Blood test may spare throat cancer patients from unnecessary radiation

This study looks at whether a simple blood test can tell which throat cancer patients can safely skip radiation after surgery. About 61 people with HPV-related throat cancer will have their blood tested before and after surgery. If the test is negative after surgery and they are …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control

Last updated May 14, 2026 12:04 UTC

New drug duo aims to fight hard-to-treat head and neck cancer

This study tests a combination of two drugs, ACR-368 and low-dose gemcitabine, in people whose head and neck cancer has come back or spread. The goal is to see if the treatment can shrink tumors and slow the disease. About 43 participants will receive the drugs every two weeks as…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated May 14, 2026 12:04 UTC

New drug ALE.P02 targets tough cancers in early trial

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to target a protein called Claudin-1 found on these cancer cells. The main goals are to check the drug's safety, find th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control

Last updated May 14, 2026 12:04 UTC

New drug combo targets Hard-to-Treat cancers in early trial

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control

Last updated May 14, 2026 12:03 UTC

New hope for hard-to-treat cancers? first human trial launches

This early-stage study tests a new drug called azirkitug, alone or with other medicines, in people with advanced solid tumors like lung, head/neck, and other cancers. The goal is to find safe doses and check side effects. About 694 adults will take part at sites worldwide.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control

Last updated May 14, 2026 12:01 UTC

New pill hopes to unleash immune system against tough cancers

This early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control

Last updated May 13, 2026 16:03 UTC

New drug combo targets Hard-to-Treat cancers in early trial

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control

Last updated May 13, 2026 16:03 UTC

New drug combo aims to boost immune response in Hard-to-Treat cancers

This study tests whether adding an experimental drug (GB1211) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma or head and neck cancer. About 92 participants will receive either the combination or a placebo plus pem…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control

Last updated May 13, 2026 16:03 UTC

New drug EPI-326 enters human testing for tough cancers

This early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control

Last updated May 13, 2026 16:02 UTC

New pill shows promise for Hard-to-Treat brain cancers

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control

Last updated May 13, 2026 15:59 UTC

New drug combo shows promise for Hard-to-Treat cancers

This study tests a new drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers that have spread. The goal is to see if the drug can shrink tumors and control the disease. About 257 adults wit…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated May 13, 2026 15:58 UTC

New drug combo before surgery shows promise against head and neck cancer

This study tests whether giving two drugs (pembrolizumab and IO102-103) before surgery is safe and effective for people with head and neck cancer that can be removed. About 30 adults with newly diagnosed or returning cancer will receive the drug combination, then have surgery. Re…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated May 12, 2026 13:47 UTC

New drug KIVU-107 targets Hard-to-Treat cancers in early trial

This study tests a new drug called KIVU-107 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to find the safest dose and check fo…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control

Last updated May 12, 2026 13:42 UTC

Could a Two-Drug punch before surgery beat head and neck cancer?

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 12, 2026 13:40 UTC

New combo therapy aims to shrink head and neck tumors better than standard treatment

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer or shrink their tumors more than pembrolizumab alone. About 700 adults whose cancer has spread or returned and whose tumors have a …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated May 12, 2026 13:40 UTC

Radioactive injection targets Hard-to-Treat cancers in early trial

This early-phase study tests a radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 22 par…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated May 11, 2026 20:48 UTC

New drug IDE034 targets Hard-to-Treat cancers in early trial

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control

Last updated May 08, 2026 12:03 UTC

Could a drug combo before surgery eliminate the need for radiation in head and neck cancer?

This early-phase study is testing whether adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe and effective for people with advanced head and neck cancer. The goal is to see if this approach might allow patients to skip radiat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated May 08, 2026 12:03 UTC

New hope for advanced cancers? early trial of DR-0202 begins

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control

Last updated May 08, 2026 12:00 UTC

Off-the-Shelf cell therapy takes on Hard-to-Treat cancers

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated May 07, 2026 18:40 UTC

Engineered immune cells take aim at Hard-to-Treat cancers

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated May 06, 2026 16:14 UTC

New radiation drug targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated May 06, 2026 16:14 UTC

New combo tackles returning head and neck cancer

This study is for people whose head and neck cancer has come back after previous treatment. It tests a new combination of drugs (tislelizumab and pamiparib) given together with chemotherapy and a second round of radiation. The main goal is to find the safest dose and see if this …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control

Last updated May 04, 2026 16:24 UTC

New hope for head and neck cancer: drug works after immunotherapy fails

This study tests whether the drug cetuximab can shrink tumors in people with head and neck cancer that has spread or come back, after they have already tried immunotherapy. About 38 adults will receive cetuximab alone. The main goal is to see how many patients' tumors shrink or d…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control

Last updated Apr 30, 2026 15:48 UTC

Scientists unleash engineered immune cells and Cancer-Killing virus in First-of-Its-Kind trial

This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control

Last updated Apr 08, 2026 12:03 UTC

New scan could spot hidden cancer spread in head and neck patients

This study tests a new imaging drug called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new imaging agent…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis

Last updated May 16, 2026 22:26 UTC

Glow-in-the-Dark dye could help surgeons find hidden cancers

This study is testing a special dye called pegsitacianine that makes cancer cells glow during surgery. About 120 adults with head and neck cancer will receive one dose before their operation. Doctors will use cameras to see if the dye helps find tumors that are hard to detect, es…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis

Last updated May 15, 2026 11:55 UTC

Double vision: new imaging combo could help surgeons spot hidden cancer cells

This early-phase trial tests whether combining two imaging techniques can help surgeons find and remove head and neck cancer more completely. About 40 adults with squamous cell carcinoma will receive a radioactive tracer and a fluorescent dye that both attach to cancer cells. Bef…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated May 11, 2026 20:51 UTC

New imaging agent could spot hidden cancer in neck lymph nodes

This early-stage trial tests a radioactive drug called 111In-panitumumab to see if it can better find cancer that has spread to lymph nodes in people with head and neck cancer. About 30 adults scheduled for surgery will receive the drug and then get a special scan (SPECT/CT) to s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated May 04, 2026 16:23 UTC

Scientists test 'Tumor Spotlight' scan for better cancer detection

Prevention Recruiting now

This is a small, early-stage study to see if a new type of imaging scan can more accurately find and measure head and neck cancer tumors before surgery. Researchers will compare the new scan, which uses a special tracer drug, to the standard scan that is already used. The study i…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Diagnosis

Last updated Apr 17, 2026 16:10 UTC

Ice microneedle patch aims to stop radiation skin scarring in cancer patients

This early-stage trial tests whether a protein called CFH, delivered through ice microneedles, can prevent skin hardening (fibrosis) caused by radiation therapy. Nine adults with head and neck cancer who will receive radiation after surgery will get the patches twice a week for f…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention

Last updated May 15, 2026 11:53 UTC

New study tests gabapentin to curb opioid use for cancer mouth sores

This study tests whether a high dose of gabapentin, a nerve pain medication, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 adults with squamous cell carcinoma of the head …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated May 16, 2026 22:32 UTC

New drug aims to ease painful mouth sores for head and neck cancer patients

This study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to improve quality of life…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief

Last updated May 16, 2026 22:28 UTC

Heat boost for radiation: new combo therapy tested in incurable cancers

This study tests whether adding a special heat treatment (water-filtered infrared-A, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancers that cannot be cured. About 60 adults will receive the combi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: King's College London • Aim: Symptom relief

Last updated May 16, 2026 22:28 UTC

Can a nutrition drink ease chemo side effects? new study aims to find out

This study tests whether a special dietary supplement can reduce severe side effects from standard cancer treatments in people with head and neck, lung, or rectal cancer. About 52 participants will take the supplement during their treatment, and their results will be compared to …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief

Last updated May 16, 2026 22:27 UTC

New radiation approach aims to shrink tumors faster for head and neck cancer patients

This study tests whether a shorter course of high-dose radiation (SBRT) can safely reduce symptoms in people with head and neck cancer that cannot be cured. About 108 adults with squamous cell carcinoma of the head and neck will receive either standard or shorter radiation. The m…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated May 16, 2026 22:26 UTC

New hope for cancer patients: drug may curb appetite loss during treatment

This study tests whether adding olanzapine to standard nausea care can better manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults with this cancer will receive either olanzapine plus standard care or standard care alone. The main goal …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief

Last updated May 15, 2026 11:57 UTC

Could a constipation drug help head and neck cancer patients before surgery?

This study is testing whether a drug called methylnaltrexone, which is normally used for constipation, can be safely given to people with head and neck cancer for two weeks before their surgery. The main goal is to check for side effects. About 25 adults with oral cavity cancer t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated May 13, 2026 16:02 UTC

Can a buried fat flap soothe neck pain after cancer? small study aims to find out

This pilot study tests whether a buried fat flap (taken from the thigh) is safe and helpful for reducing neck problems like pain, stiffness, swelling, and trouble swallowing after head and neck cancer treatment. About 12 adults who need a second neck surgery after radiation will …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief

Last updated May 07, 2026 18:39 UTC

Heavy lifting may boost recovery for head and neck cancer survivors

This study tests whether a heavy lifting strength training program can help head and neck cancer survivors regain muscle strength, reduce fatigue, and improve quality of life. About 60 adults who finished cancer treatment at least one year ago will be randomly assigned to either …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Alberta • Aim: Symptom relief

Last updated May 05, 2026 11:55 UTC

Cancer Patients' nutrition under the microscope: study aims to improve treatment support

This study observes 110 adults with head/neck, lung, or rectal cancer to track changes in their nutrition and body composition during standard cancer treatments. Researchers measure daily food intake, muscle mass, and strength over time. The goal is to gather information that wil…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused

Last updated May 16, 2026 22:31 UTC

Virtual reality could make head and neck cancer surgery more precise

This study tests whether using virtual reality (VR) and 3D models before surgery helps doctors plan better and improve outcomes for people with head and neck cancer. About 160 adults scheduled for surgery will take part. The goal is to see if this technology reduces the chance of…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused

Last updated May 16, 2026 22:29 UTC

Tiny tumor clones could guide cancer drug choices

This study is testing whether tiny, lab-grown copies of a patient's tumor (called organoids) can accurately predict which cancer drugs will work best for that person. Researchers will compare the organoid test results with how the patient actually responds to treatment. The goal …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Huashan Hospital • Aim: Knowledge-focused

Last updated May 16, 2026 22:26 UTC

New imaging study reveals hidden vascular damage from radiation in head and neck cancer

This study uses special PET/CT scans to see how radiation therapy affects blood vessels in the neck of people with head and neck cancers. About 20 adults will get two types of PET scans before and after radiation. The goal is to compare the scans and learn more about radiation's …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused

Last updated May 15, 2026 11:56 UTC

500 cancer patients to help unlock secrets of head and neck tumors

This study is for 500 adults with advanced head and neck squamous cell carcinoma who are starting standard immunotherapy. Researchers will collect blood and tumor samples over time to study genetic and immune markers. The goal is to better understand which patients respond to tre…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Tempus AI • Aim: Knowledge-focused

Last updated May 15, 2026 11:54 UTC

New imaging tracer could light up tumors for better detection

This study is testing whether a new radioactive imaging agent can safely and clearly show tumors in people with many types of solid cancers. About 32 adults will receive a single injection of the agent and then have PET/CT scans to see where it goes in the body. The goal is to le…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Var2 Pharmaceuticals • Aim: Knowledge-focused

Last updated May 11, 2026 20:40 UTC

Remote hearing tests could save cancer Patients' hearing

This study looks at whether offering hearing tests close to home or remotely can help more head and neck cancer patients get their hearing checked during and after treatment. Many patients on cisplatin chemotherapy or radiation may lose hearing, but traveling to the clinic for te…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused

Last updated May 11, 2026 20:38 UTC

New MRI study aims to sharpen radiation for head and neck tumors

This study looks at how MRI scans can help doctors see changes in head and neck tumors during radiation therapy. About 173 people with newly diagnosed head and neck cancer will get extra MRI scans while receiving standard treatment. The goal is to learn how to better target radia…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused

Last updated May 07, 2026 18:41 UTC

New program aims to cut delays in cancer radiation after surgery